Advaxis submitted an Application for Orphan Drug Designation to the FDA for ADXS-HPV, a drug candidate for the treatment of human papillomavirus (HPV)-associated head and neck cancer.

ADXS-HPV is currently being evaluated in a Phase 1/2 study in HPV-positive head and neck cancer in the United Kingdom and one will be initiated in the United States this year.

ADXS-HPV is an immunotherapy that is designed to target cells expressing the HPV gene E7. Expression of the E7 gene from high-risk HPV variants is responsible for the transformation of infected cells into dysplastic and malignant tissues. Eliminating these cells can eliminate the dysplasia or malignancy.

For more information call (609) 452-9813 or visit www.advaxis.com.